Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma.

Abstract

In The Lancet Oncology, Nathalie Gaspar and colleagues 1 Gaspar N Venkatramani R Hecker-Nolting S et al. Lenvatinib with ifosfamide plus etoposide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, phase 1/2 study. Lancet Oncol. 2021; (published online Aug 17.)https://doi.org/10.1016/S1470-2045(21)00387-9 Summary Full Text Full Text PDF PubMed Google Scholar report safety and activity data from the ongoing phase 1/2 ITCC-050 trial (NCT02432274), in which patients with refractory or relapsed osteosarcoma were given lenvatinib with etoposide plus ifosfamide. The authors should be congratulated for the study design and combining systemic cytotoxic chemotherapy with a tyrosine kinase inhibitor. This study will have an impact on future trials in patients with advanced pretreated osteosarcoma, which constitutes a population with an unmet need in clinical oncology. Notably, Gaspar and colleagues report a median progression-free survival of 8·7 months (95% CI 4·5–12·0) and progression-free survival at 4 months of 51% (34–69) for patients receiving lenvatinib with etoposide plus ifosfamide. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 studyLenvatinib with etoposide plus ifosfamide shows promising antitumour activity with no new safety signals in patients with refractory and relapsed osteosarcoma. These findings warrant further investigation in an ongoing randomised phase 2 study (NCT04154189). Full-Text PDF